- $3.91bn
- $8.71bn
- $7.11bn
- 72
- 83
- 13
- 57
Annual income statement for Concentrix, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2019 November 30th | 2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,708 | 4,720 | 5,587 | 6,324 | 7,115 |
| Cost of Revenue | |||||
| Gross Profit | 1,748 | 1,662 | 1,969 | 2,257 | 2,578 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4,414 | 4,411 | 5,015 | 5,684 | 6,509 |
| Operating Profit | 294 | 309 | 572 | 640 | 605 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 204 | 268 | 556 | 605 | 408 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 117 | 165 | 406 | 436 | 314 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 117 | 165 | 406 | 435 | 314 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 117 | 165 | 400 | 428 | 308 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.06 | 3.64 | 7.99 | 8.75 | 7.51 |
| Dividends per Share |